SPRB
Spruce Biosciences, Inc.
45.40$
-0.6%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
Spruce Biosciences, Inc. (SPRB) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -22 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.2 | -4.2 | -1.3 | -2.9 | -6.0 | -4.7 | -7.6 | -9.3 | -8.8 | -9.7 | -7.6 | -9.8 | -12 | -9.5 | -8.6 | -12 | -12 | 2.0 | -12 | -11 | -15 | -11 | -9.2 | -21 | -13 | -8.8 | -5.3 | -6.5 | -8.7 | -22 | -43 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.6 | 0.9 | |
| 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.2 | 0.4 | 1.1 | 1.0 | 1.0 | 0.8 | 1.1 | 0.9 | 0.8 | 0.8 | 1.1 | 1.2 | 1.1 | 1.2 | 1.6 | 1.7 | 1.1 | 1.0 | 0.5 | -0.1 | 0.4 | 1.7 | 0.7 | 0.9 | 3.7 | |
| 0.0 | 0.0 | 0.1 | – | 0.0 | 0.1 | 0.2 | 0.4 | 1.2 | 1.1 | 1.2 | 0.9 | 1.3 | 1.0 | 0.9 | 0.1 | 1.1 | 1.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.2 | -0.2 | 1.2 | 0.3 | -0.8 | -0.9 | 1.7 | -1.4 | -0.1 | 1.0 | 0.7 | 1.0 | -1.4 | 1.3 | 1.9 | -0.7 | 0.0 | 14 | -1.0 | -2.5 | -5.0 | -3.7 | -1.8 | 1.8 | 0.9 | -6.3 | 2.3 | 2.4 | 2.4 | -5.4 | 1.7 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -61 | -12 | -6.0 | -7.5 | 34 | -17 | 15 | 10 | 22 | 14 | 9.3 | – | – | – | – | – | – | – | – | 0.0 | -0.1 | – | |
| – | – | – | – | – | – | – | – | – | – | – | 5.2 | – | – | – | – | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | 0.1 | 0.2 | – | 0.1 | – | – | 0.0 | 0.1 | 0.0 | -0.1 | – | -0.2 | 0.0 | 0.0 | – | – | – | – | 0.0 | 0.0 | – | 0.0 | – | |
| – | – | 2.5 | – | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | – | – | -0.4 | -0.4 | -0.4 | -0.4 | – | – | – | – | -0.4 | -0.4 | -0.4 | -0.4 | -0.4 | -0.8 | 14 | 0.0 | 13 | |
| 4.0 | 4.0 | 2.5 | 2.0 | 44 | -0.1 | 43 | 94 | 0.3 | 0.2 | 0.0 | 0.2 | -0.1 | -0.1 | -0.1 | 0.0 | 51 | -0.4 | -0.4 | -0.6 | -0.2 | -0.4 | -0.4 | -0.6 | -0.4 | -0.4 | -0.4 | 45 | 14 | 64 | 123 | |
| -0.2 | -0.2 | 1.2 | -0.9 | 38 | -4.8 | 36 | 85 | -8.5 | -70 | -20 | -16 | -19 | 24 | -26 | 3.1 | 49 | 24 | 1.3 | -2.5 | -15 | -11 | -9.6 | -21 | -13 | -9.2 | -5.7 | 38 | 5.2 | 42 | 80 | |
| -4.2 | -4.2 | -1.3 | -2.9 | -6.0 | -4.7 | -7.6 | -9.3 | -8.8 | -9.7 | -7.7 | -9.8 | -12 | -9.5 | -8.6 | -12 | -12 | 2.0 | -12 | -11 | -15 | -11 | -9.2 | -21 | -13 | -8.8 | -5.3 | -6.5 | -8.7 | -22 | -43 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.